Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Triptorelin + chemotherapy refers to a treatment regimen combining triptorelin, a gonadotropin-releasing hormone (GnRH) agonist, with chemotherapy. This combination is primarily used as an adjuvant treatment for hormone-responsive early-stage breast cancer in premenopausal women at high risk of recurrence, particularly those who remain premenopausal after chemotherapy. Triptorelin suppresses ovarian function, reducing estrogen levels, which aids in controlling hormone-dependent cancer growth. Clinical trials like SOFT and TEXT have demonstrated that adding triptorelin (for ovarian function suppression) to endocrine therapy (tamoxifen or aromatase inhibitors) provides significant disease control benefits, especially in higher-risk patients post-chemotherapy. Additionally, triptorelin may be used with chemotherapy for fertility preservation in premenopausal women receiving curative treatment for cancer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on triptorelin + chemotherapy.